<DOC>
	<DOCNO>NCT00888901</DOCNO>
	<brief_summary>This single-center , prospective , control study one eltrombopag treatment group 2 control group , one standard steroid treatment , another one untreated . The aim study determine effect Thrombopoietin Receptor ( MPL ) agonists shear-induced platelet activation .</brief_summary>
	<brief_title>Platelet Function Idiopathic Thrombocytopenic Purpura ( ITP ) Patients With Eltrombopag</brief_title>
	<detailed_description>STUDY DESIGN : Single-center ( Medical University Vienna ) , prospective , control study . Patients recruit Division Haematology Haemostaseology Medical University Vienna , one eltrombopag treatment group 2 control group , one standard steroid treatment , another one untreated . AIM OF THE STUDY : To determine effect MPL agonists shear-induced platelet activation . Data obtain patient treated eltrombopag shall compare untreated patient patient steroid . These investigation extend previous study investigate platelet function without vitro activation patient receive eltrombopag . PATIENTS : Trial Population : Total number patient n=34 : 12 eltrombopag , 12 corticosteroid 10 without treatment include trial . Treatment eltrombopag corticosteroid . Eltrombopag start dose : 25 mg/day , increase need ( 50 mg maximum 75 mg daily ) every 2 week reach platelet count 50,000-100000/µL taper dosis platelet count &gt; = 100,000/µL . Afterwards , platelet count stable ( tolerance +/- 20 % ) , platelet control every 4 week , otherwise weekly . Prednisolone start dose : 1 mg/kg/day reach platelet count 50,000-100,000 /µL taper dosage platelet count &gt; = 100,000/µL . Laboratory Investigations : In eltrombopag group newly treat prednisolone group platelet count platelet function test perform planned visit . In patient continuous corticosteroid ( part control group I ) untreated patient ( control group II ) , platelet count 50,000 100,000/µL platelet count , reticulate platelet , platelet function test platelet antibody study entry 4 week ( + 5 day ) .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion Criteria ( group ) : Male female patient establish chronic autoimmune thrombocytopenia ( cAITP ) Age ≥ 18 ≤ 90 year Females , pregnant , nurse consent perform safe anticontraception Written consent study related procedure Inclusion Criteria ( patient treat eltrombopag ) : Platelet count &lt; 50,000 /µL screen At least one prior alternative cITP therapy Inclusion Criteria ( patient treat corticosteroid Control group 1 ) : Platelet count &lt; 50,000 /µL history At least 50 % patient &lt; 50,000 /µL inclusion follow 3 month Inclusion Criteria ( patient untreated Control group 2 ) : Platelet count &lt; 50,000 /µL history At screen platelet count 50,000 100,000 /µL Exclusion Criteria ( patient ) : History venous arterial thromboembolism stroke Known coronary heart disease cardiac arrythmias Known HIV Hepatitis C infection Impaired liver function define elevated ALT &gt; 1.5 UNL , bilirubin ULN , albumin less normal value Prothrombin time less normal value Elevated creatinine level ( &gt; 1.3 ULN ) Unable/unwilling follow protocol Previous active malignancy Patients include study eltrombopag time Patients treat another investigational product within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ITP</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>platelet function</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>Platelet function patient cAITP eltrombopag</keyword>
</DOC>